

1 **Title:** Transcriptional response to West Nile virus infection in the zebra finch
2 (*Taeniopygia guttata*), a songbird model for immune function

3
4 **Authors:**

5 Daniel J Newhouse^{1*}, Erik K Hofmeister², Christopher N Balakrishnan¹

6
7 ¹ Howell Science Complex, East Carolina University, Greenville, North Carolina, 27858,
8 USA

9 ² U.S. Geological Survey, National Wildlife Health Center, 6006 Schroeder Road,
10 Madison, Wisconsin 53711, USA

11 * Corresponding Author: newhoused12@students.ecu.edu

12
13
14
15
16

17 West Nile Virus (WNV) is the one of most widespread arboviruses
18 worldwide. WNV exists in a bird-mosquito transmission cycle where passerine birds
19 act as the primary reservoir host. As a public health concern, the mammalian
20 immune response to WNV has been studied in detail. Little, however, is known
21 about the avian immune response to WNV. Avian taxa show variable susceptibility
22 to WNV and what drives this variation is unknown. Thus, to study the immune
23 response to WNV in birds, we experimentally infected captive zebra finches
24 (*Taeniopygia guttata*). Zebra finches provide a useful model, as like many natural
25 avian hosts they are moderately susceptible to WNV and thus provide sufficient
26 viremia to infect mosquitoes. We performed splenic RNAseq during peak viremia to
27 provide an overview of the transcriptional response. In general, we find strong
28 parallels with the mammalian immune response to WNV, including up-regulation of
29 five genes in the Rig-I-like receptor signaling pathway, and offer insights into avian
30 specific responses. Together with complementary immunological assays, we
31 provide a model of the avian immune response to WNV and set the stage for future
32 comparative studies among variably susceptible populations and species.

33

34 **Introduction:**

35 West Nile virus (WNV) is a single-stranded RNA flavivirus that exists in an
36 avian-mosquito transmission cycle, where birds (typically Passeriformes) act as the
37 primary amplification hosts. In addition to birds, nearly 30 other non-avian vertebrate
38 species have been documented as hosts (1). Although many WNV-infected hosts are
39 asymptomatic, WNV infection can cause severe meningitis or encephalitis in those that

40 are highly susceptible. Avian species for the most part exhibit low to moderate
41 susceptibility. That is, individuals become infected and develop sufficient viremia for
42 transmission via mosquito blood meal, but the hosts recover and avoid significant
43 mortality, reviewed in (2). First described in 1937, WNV has not resulted in widespread
44 avian decline throughout its historical range (3), perhaps due to host-parasite coevolution.
45 However, the emergence of WNV in North America in 1999 has negatively impacted a
46 wide range of populations (4,5). Surveys of North American wild birds have shown a
47 variety of competent WNV hosts, with varying degrees of susceptibility, morbidity, and
48 pathogenicity (2). American robins (*Turdus migratorius*) appear to be the main host in
49 spreading WNV infection in North America (6), but infection appears most detrimental to
50 members of Family Corvidae (7). Despite great variation in susceptibility, the
51 mechanisms underlying this variation are primarily unknown (2).

52

53 Largely due to interest in human health implications, most work describing the
54 host immune response to WNV infection has been performed in mammalian systems (8).
55 From these studies, we know that in mammals, both the innate and adaptive arms are
56 critical for virus detection and clearance (9,10). Within the innate immune response, the
57 retinoic acid-inducible gene 1(Rig-I)-like receptor (RLR) pathway appears to play a key
58 role in viral clearance. This pathway recognizes viral products and initiates type I
59 interferon expression (11). Mice lacking the viral recognition RLR genes in this pathway,
60 DDx58 (Rig-I) and IFIH1 (MDA5), become highly susceptible to WNV infection (12). In
61 the adaptive immune system, a broad range of components appear to play important roles
62 in mounting a response, including antibody and CD4+ and CD8+ T cells (9,13,14).

63 Interestingly, major histocompatibility complex (MHC) class I genes are up-regulated
64 post-infection (15,16). Viruses typically evade MHC class I detection (17,18), as MHC
65 class I molecules bind and present viral peptides to CD8⁺ T cells. However, the purpose
66 of WNV induced MHC expression is unclear.

67

68 While the mammalian immune response to WNV infection has been extensively
69 studied, the avian immune response remains mostly unknown. Of the studies in birds,
70 many involve experimentally infecting wild caught birds, reviewed in (2), or domestic
71 chickens (*Gallus gallus*) (19). These studies primarily focus on viral detection, tissue
72 tropism, antibody production, or lymphocyte counts (2,19,20). Little is known about the
73 molecular mechanisms driving the immune response to WNV infection, but see (21).
74 Furthermore, current avian WNV studies suffer many challenges. Wild caught birds may
75 be co-infected with other parasites (e.g. avian malaria) and are difficult to maintain in
76 captivity for experimental infection studies. Chickens, although an avian model species,
77 are highly resistant to WNV infection (22), uncommon hosts, and therefore are not ideal
78 to describe the avian immune response to WNV infection. Passeriformes and Galliformes
79 are also highly divergent bird lineages, with distinctive immune gene repertoires and
80 architecture (23).

81

82 As passerine birds are the main hosts for WNV, we have sought to develop a
83 passerine model to study the impacts of WNV infection on a taxonomically appropriate
84 host (24). We have recently shown that zebra finches, *Taeniopygia guttata*, are
85 moderately susceptible hosts for WNV (25). That is, WNV rapidly disseminates to a

86 variety of tissues and is detectable in most samples by four days post-inoculation (dpi).
87 Despite rapid development of sufficient viremia for arthropod transmission, zebra finches
88 develop anti-WNV antibodies, clear WNV by 14dpi, and avoid significant mortality (25).
89 This moderate disease susceptibility is similar to what is observed in many natural WNV
90 hosts. Zebra finches are also an established biomedical model system with a suite of
91 genetic and genomic tools available (26).

92

93 In this study, we experimentally infected zebra finches and performed splenic
94 RNAseq to describe their transcriptional response over the time course of infection. In
95 doing so, we characterize the zebra finch immune response to WNV infection, explore
96 expression of the avian RLR pathway in response to WNV, gain insights into the avian
97 immune response to this widespread infectious disease, and uncover conserved
98 evolutionary responses in avian and mammalian systems.

99

100 **Results**

101 *Experimental infection*

102 We challenged six individuals with with 10^5 plaque forming units (PFU) WNV
103 and sequenced RNA (Illumina RNAseq) isolated from spleens, an organ critical to the
104 avian immune response. Three birds served as procedural controls and on day 0 were
105 injected subcutaneously with 100 μ L of BA1 media, as previously described (27).
106 Peak viremia occurs at 4.6 ± 1.7 dpi as quantified via RT-PCR (25) and thus, we
107 characterized the transcriptional response leading to (2dpi, n=3) and at peak viral load
108 (4dpi, n=3) in the present study. WNV RNA was detected by culture in lung and kidney

109 RNA pools of 2 out of 3 birds sampled at day 2, and all 3 birds sampled at 4dpi. These
110 findings were verified by semi-quantitative RT-PCR. Because WNV is rarely detected in
111 spleen by 2dpi, but all birds previously inoculated at 10^5 PFU developed WNV antibodies
112 [25] we treated all six birds inoculated with WNV as being infected.

113

114 *Sequencing results & read mapping*

115 We obtained 18-30 million paired-end, 100bp reads for each sample and removed
116 0.57-1.24% of the total bases after adapter trimming (Supplementary Table S1). On
117 average, 79.0-80.8% total trimmed reads mapped to the zebra finch reference genome
118 (Supplementary Table S2), corresponding to 18,618 Ensembl gene IDs. Of these, 14,114
119 genes averaged at least five mapped reads across all samples and were utilized for
120 differential expression (DE) analyses.

121

122 *Sample clustering & differential expression*

123 We tested for DE two ways: as pairwise comparisons between treatments to
124 identify specific genes with *DEseq2* (28) and as a time-course grouping genes into
125 expression paths with *EBSeqHMM* (29). To visualize patterns of expression variation
126 among samples, we conducted principal component analysis (PCA) and distance-based
127 clustering (Supplemental Figures S1 & S2). The first three principal components
128 explained 93.04% of the variance in gene expression, but none of the PCs were
129 significantly correlated with treatment (ANOVA, PC1: $p = 0.288$, PC2: $p = 0.956$, PC3: p
130 $= 0.202$). Although this finding suggests that much of the expression variation was

131 independent of the experimental treatment, pairwise comparisons revealed genes that
132 were DE between treatments.

133

134 When comparing Control vs. 2dpi, we found 161 differentially expressed genes
135 (adjusted $p < 0.10$, average \log_2 fold-change (FC) = 1.74). This gene list includes several
136 immune related genes associated with the innate (e.g. IL18) and adaptive (e.g. MHC IIB)
137 immune system (Table 1, Figure 1). Sixty-five genes were differentially expressed
138 between Control and 4dpi (average \log_2 FC = 1.61), also with several immune relevant
139 genes including five genes in the RLR pathway (Table 1, Figure 2, Figure 3). Lastly, we
140 observed 44 DE genes between 2dpi vs. 4dpi individuals (average \log_2 FC = 1.56). Three
141 of these have described functions in immunity. The complete list of *DEseq2* DE genes
142 (adjusted $p < 0.10$) across all comparisons can be found in Supplementary Table S3 and
143 immune relevant DE genes are listed in Table 1 along with their gene name, \log_2 fold
144 change, padj value, and comparison to mammalian studies. We also combined 2dpi and
145 4dpi cohorts and compared with control, but due to high variation in gene expression
146 between days 2 and 4 dpi, we only found 16 DE genes (average \log_2 FC = 1.64) between
147 Control and Infected cohorts, one of which was associated with immunity.

148

149 When analyzed for DE as a time course in *EBSeqHMM*, 686 genes showed
150 evidence of differential expression (posterior probability > 0.99 , FDR < 0.01). Most DE
151 genes ($n = 561$) were suppressed following infection (“Down-Down”) or varied between
152 conditions. Seventy-five genes were “Up-Down”, 49 were “Down-Up” and 1 was “Up-
153 Up”. As expected, we found overlap of several immune genes between the two analyses.

154 For example, IL18, APOD and IFITM10 are “Up-Down” (Supplementary Table S5) and
155 this trend is reflected in the *DEseq2* Control vs 2dpi analysis (Figure 1).

156

157 *Functional annotation of differentially expressed genes*

158 To place differentially expressed genes into groups based on their biological
159 function, we performed a gene ontology (GO) analysis using the *GOfinch* tool (30). As
160 above, we conducted GO analyses based on multiple pairwise analyses of gene
161 expression. The strongest evidence of functional enrichment was observed in the contrast
162 of Control vs. 4dpi. This list of 65 differentially expressed genes showed functional
163 enrichment of 55 GO terms (Fisher’s Exact Test, FDR $p < 0.05$ (Benjamini Hochberg
164 method [31])). It is in this contrast where the immune response manifests itself most
165 strongly, with a large list of immune-related categories (Supplementary Table S4) and a
166 broad range of immune functioning genes differentially expressed ($n=14$, Tables 1 & 2).
167 When comparing genes differentially expressed between Control and 2dpi, only one GO
168 category was strongly enriched (“integral to membrane”, expected = 15, observed = 35, p
169 = 0.00065). In this contrast we also observed several slightly enriched immune related
170 GO categories such as “inflammatory response” and “negative regulation of T cell
171 migration” but these fall outside of our significance threshold (Supplementary Table S4)
172 and reflect only few genes (e.g. APOD and IL18) that were DE in the Control vs. 2dpi
173 analysis. A set of 57 enriched GO categories describe genes DE between 2 and 4dpi.
174 Although some of these involved T and B cell regulation, these categories were also only
175 represented by a single gene each (ADA) (Table 2, Supplementary Table S4). We found

176 no evidence of functional enrichment among DE genes between Control vs. Infected
177 (2dpi and 4dpi) cohorts.

178

179 We also conducted a similar analysis of genes identified as DE by *EBseqHMM*,
180 which revealed two (Up-Up), 107 (Up-Down), 12 (Down-Up) and 73 (Down-Down)
181 significantly enriched GO categories (adjusted $p < 0.05$, Supplementary Table S5).
182 Interestingly, Up-Down GO categories had the strongest representation of immune
183 related GO terms, including “cytokine receptor activity” (expected = 0, observed = 3 $p =$
184 0.015) and “positive regulation of interferon-gamma production” (expected = 0, observed
185 = 2, $p = 0.028$). However, we also observed a strong immune signature among Down-
186 Down Genes (GO Term “Immune Response”, expected = 3, observed = 11, $p = 0.013$),
187 which represents several innate immune genes including three complement genes and
188 interferon gamma. Twelve categories were significantly enriched among “Down-Up”
189 genes, including “double-stranded RNA binding” (expected = 0, observed = 2, adjusted p
190 = 0.049). One of the observed genes in this category is OASL, which has been
191 demonstrated to have antiviral activity towards WNV in chickens (21). Lastly, as in the
192 *DEseq2*-based analysis, we also detected a strong enrichment signature of membrane
193 proteins. Genes annotated as “integral to membrane” were highly enriched among those
194 showing an Up-Down pattern (expected = 6, observed = 14, adjusted $p < 0.028$,
195 Supplementary Table S5). Combined, we find broad overlap in GO representation
196 between the *EBseqHMM* and *DEseq2* approaches.

197

198 In addition to placing genes into broad systematic functions in the GO analysis,
199 we were also interested in placing our gene expression results in the context of immune
200 pathways of interest. The RLR antiviral pathway is critical to WNV clearance in
201 mammals (12) and appears important in mounting an immune response to avian influenza
202 in ducks (32-34). Utilizing *Pathview v1.8.0* (35), we find that WNV infection induces the
203 RLR pathway. Five genes, including the two RLR genes, DDx58 and IFIH1, which
204 encode the Rig-I and MDA5 viral detection molecules, are significantly up-regulated
205 (Table 1, Figure 3, Supplementary Figure S3). We detect expression of 36/37 genes in the
206 pathway, many of which are also up-regulated, though not always significantly.

207

208 *De novo transcriptome analysis*

209 To reveal any genes responding to infection missed by our genome based
210 analysis, we created a reference transcriptome with *Trinity v2.1.1* (35) and annotated
211 against the NCBI non-redundant database with *DIAMOND*, a *BLASTx*-like aligner (37).
212 Our *de novo* transcriptome assembly resulted in 393,408 *Trinity* transcripts. We
213 visualized our annotated transcriptome with *MEGAN* (38), which places genes into
214 KEGG pathways. In doing so, we confirmed many expression results from the genome-
215 based approach and importantly, this analysis revealed expression of two transcripts with
216 homology to interferon alpha, which was absent (but annotated) in the genome based
217 analysis described above. Combined, our genome-based and reference-free approaches
218 detect regulation of the complete RLR pathway in zebra finches.

219

220 **Discussion**

221 We have characterized the zebra finch transcriptional response to WNV infection.
222 Overall, we find that as in mammalian systems, components of both the adaptive and
223 innate immune pathways are activated following infection. While WNV is primarily an
224 avian specific infectious disease, most work describing the host immune response to
225 infection has been performed in mammals. Despite genomic, physiological and
226 evolutionary differences between birds and mammals, the host immune response shows
227 broad similarity between taxa (Table 1).

228

229 We were particularly interested in the role of the innate RLR pathway. This
230 pathway mounts an antiviral innate immune response and is critical for WNV detection
231 and clearance in mammals (12). By combining genome and transcriptome-based
232 approaches, we show here that the RLR pathway in zebra finches is induced by WNV
233 infection, as gene expression is detected throughout the pathway. Furthermore, five genes
234 in this pathway are significantly up-regulated at 4dpi (Figure 3, Supplementary Figure
235 S3), including IFIH1 and DDx58 (Figure 2B), which encode molecules that recognize
236 WNV particles in mammals (39). This results in a corresponding over-representation of
237 genes in the RLR pathway GO categories (Table 2). While no studies have investigated
238 the role of the RLR following WNV infection in birds, this pathway appears important
239 for avian influenza clearance in ducks (32-34), Buggy Creek virus clearance in house
240 sparrows (39), and likely for the broad avian antiviral immune response, including WNV.

241

242 We observed other parallels with mammals as well (Table 1). For example, T-Cell
243 Immunoglobulin Mucin Receptor 1 (TIM1) is up-regulated at 2dpi in zebra finches

244 (Figure 1A, C). In human cell lines, expression of TIM1 promotes infection of WNV
245 virus like particles (VLPs) (41,42), suggesting that the up regulation of TIM1 seen in
246 zebra finches may promote viral entry as well. Similarly, C-C motif chemokine
247 (ENSTGUG00000005295) is up-regulated in our study at 2dpi and in previous human
248 cell line and mouse experiments, suggesting a conserved role in chemokine production
249 following WNV infection (43-45). Apolipoprotein D (APOD), a gene typically involved
250 in brain injury and potentially responding to the neurodegenerative nature of WNV, is up-
251 regulated in WNV infected mice (46), as well as in our study. Two interferon stimulated
252 genes (ISGs), ADAR and MOV10 are both significantly up-regulated at 4dpi relative to
253 control. Schoggins et al. (47) showed ADAR expression to enhance WNV replication and
254 MOV10 expression to have antiviral activity. While further testing of these genes is
255 needed to validate their roles in avian WNV infection, they nonetheless offer insights into
256 a broad range of conserved responses between mammals and birds.

257

258 Within the adaptive immune response, the role of the MHC in the host response to
259 WNV is also particularly interesting. The MHC plays a key role in antigen processing
260 and presentation. The MHC comprises two main classes (Class I & II) and both are up-
261 regulated in mammals following WNV infection (48,15,16). Similarly, two genes
262 encoding MHC class IIB proteins are significantly up-regulated in zebra finches at 2dpi
263 (Figure 1). Unlike mammals, however, we found that MHC class I is not significantly DE
264 in any comparison. In mammals, upregulation of MHCI may not be adaptive for the host,
265 as upregulation may actually be a mechanism by which the virus evades Natural Killer
266 (NK) cell detection by the innate immune system (15). It has also been suggested that

267 MHC up-regulation is a byproduct of flavivirus assembly (49). Interestingly, at 2dpi,
268 interleukin-18 (IL18) is significantly up-regulated (Table 1, Figure1A,B). IL18 can
269 enhance NK cell activity (50) and is potentially a mechanism by which the immune
270 system can counteract WNV evasion strategies via NK cell activation, although further
271 testing is needed to quantify NK cell activity in zebra finches to support this hypothesis.
272

273 Despite many similarities, several immune genes differentially expressed in our
274 analyses have not been previously reported in the mammalian WNV literature or are
275 expressed differently in zebra finches (Table 1). For example, at 2dpi, the
276 proinflammatory cytokine IL18 was significantly up-regulated in zebra finches (Figure
277 1), contrasting a previous study in human cell lines, which show no difference in IL18
278 expression following WNV infection (50). Furthermore, interferon regulatory factor 6
279 (IRF6) was down-regulated at 2dpi, but up-regulated in human macrophages following
280 infection (43). Another significantly down-regulated gene at 2dpi, ubiquitin carboxyl-
281 terminal hydrolase L1 (UCHL1), has been shown to suppress cellular innate immunity in
282 human cell lines infected with high-risk human papilloma virus (52). Down-regulation
283 restores functional pattern recognition receptor (PRR) pathways (e.g. RLR). The down-
284 regulation of UCHL1 here thus is associated with the previously described regulation of
285 the PRR RLR pathway in this study (Table 1). Lastly, interferon-induced protein with
286 tetratricopeptide repeats (IFIT) and interferon-inducible transmembrane proteins (IFITM)
287 gene families are known innate antiviral proteins and have been shown to restrict WNV
288 entry in human cells lines (47, 53). Both IFIT5 and IFITM10 are up-regulated (Figure
289 2A,C) in our study and yet, to our knowledge, neither have previously been implicated in

290 the host immune response to WNV. This potentially reveals an avian specific function of
291 IFIT5 and IFITM10.

292

293 Like many passerine birds infected in nature, zebra finches are moderately
294 susceptible to WNV, developing sufficient viremia to serve as competent hosts, but
295 generally resisting mortality due to infection (25). While there are clear differences
296 among treatments in terms of differentially expressed genes (Table 1), the weak effect of
297 treatment on overall expression profile (Supplemental Figure S1 & S2). may be a
298 reflection of this moderate susceptibility. Most zebra finches are able to clear WNV
299 infection by 14 dpi (25). In pairwise comparisons, there are between 16 and 161
300 differentially expressed genes, depending on the treatment comparison (Supplementary
301 Table S3). WNV infection intensity varies among tissues (20), but due to the spleen's
302 important role in the avian immune system (54,55), we expect these results to be
303 representative of the overall immune response.

304

305 Functional enrichment of several immune GO terms primarily appears in Up-
306 Down path defined by *EBseqHMM* (Supplementary Table S5), as many genes in the
307 immune system are up-regulated post-infection, as also seen in the *DEseq2* analysis
308 (Table 1, Figure 1, Figure 2). In both the *EBseqHMM* and *DEseq2* analyses, most of the
309 significant immune GO categories are innate immune responses, although adaptive
310 immune categories involved in B/T cell proliferation appear in both (Table 2,
311 Supplementary Tables S4 & S5). Similar to the mammalian model, broad organismal

312 processes, encompassing the entire immune response, are represented in the zebra finch
313 response to WNV.

314

315 The zebra finch was the second bird to have its genome sequenced (26). However,
316 the zebra finch genome assembly and gene annotation remain incomplete. Immune genes
317 in particular are difficult to reconstruct in genomes due to their complex evolutionary
318 history (e.g. MHC, [23]). Our mapping results indicated that roughly 80% of our reads
319 mapped to the genome. While the unmapped 20% could contain poor quality reads or
320 non-avian sequences, it also represents zebra finch reads that could not be appropriately
321 mapped to the reference. Thus, we took a genome-independent approach and assembled a
322 *de novo* zebra finch transcriptome from our nine paired-end samples. Interestingly, RLR
323 induced interferon expression was not detected in the genome-based analysis. The
324 transcriptome analysis, however, revealed expression of two transcripts with homology to
325 interferon alpha, thus completing the pathway from virus detection to interferon
326 production.

327

328 We have begun to develop the zebra finch as an avian model for the host response
329 to WNV infection. We show here that the zebra finch immune response is largely
330 conserved with that seen in mammalian-based studies (Table 1). Additionally, we
331 identify many components of the immune system that have not been previously
332 implicated in the host immune response to WNV. This potentially reveals an avian-
333 specific immune response and highlights avenues for future research. Combined with our
334 recent immunological characterization (25), we have broadly described the immune

335 response of a moderately susceptible avian host for WNV. This sets the stage for future
336 comparative work to uncover the genetic basis of variable avian susceptibility to WNV
337 infection.

338

339 **Methods**

340 *Experimental Setup*

341 All animal use was approved by the USGS National Wildlife Health Center
342 Institutional Animal Care and Use Committee (IACUC Protocol: EP120521) and this
343 study was performed in accordance with USGS IACUC guidelines. The experimental
344 infection setup is described in detail in (25). Briefly, nine female zebra finches were
345 randomly divided into three cohorts, one unchallenged and two challenged (n = 3 each).
346 Birds were challenged subcutaneously with 100ul BA1 media containing 10⁵ plaque-
347 forming units (PFU) of the 1999 American crow isolate of WNV (NWHC 16399-3) and
348 sacrificed at 2 and 4 dpi, corresponding to peak viremia. Uninfected individuals were
349 injected with 100ul BA1 media and sacrificed at 4dpi. WNV infection was confirmed by
350 RT-PCR, as previously described (26), in lung and kidney pooled tissue (25). Spleens
351 from each individual were removed, placed into RNAlater (Qiagen, Valencia, CA USA),
352 and frozen at -80 °C until RNA extraction.

353

354 *RNA extraction & sequencing*

355 Whole spleen tissue was homogenized in Tri-Reagent (Molecular Research
356 Company) and total RNA was purified with a Qiagen RNeasy (Valencia, CA USA) mini
357 kit following the manufacturer's protocol. RNA was DNase treated and purified.

358 Purified RNA was quality assessed on a Bioanalyzer (Agilent, Wilmington, DE USA) to
359 ensure RNA quality before sequencing (RIN = 6.6-8.1). All library prep and sequencing
360 was performed at the University of Illinois Roy J. Carver Biotechnology Center. A
361 library for each sample was prepared with an Illumina TruSeq Stranded RNA sample
362 prep kit. All libraries were pooled, quantitated by qPCR, and sequenced on one lane of an
363 Illumina HiSeq 2000 with a TruSeq SBS Sequencing Kit producing paired-end 100nt
364 reads. Reads were analyzed with Casava 1.8.2 following manufacturer's instructions
365 (Illumina, San Diego, CA). Sequencing data from this study have been deposited in the
366 NCBI Sequence Read Archive (BioProject: PRJNA352507).

367

368 *Adapter trimming & read mapping*

369 We removed Illumina adapters from reads with *Trim Galore! v0.3.7*
370 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) which makes use of
371 *Cutadapt v1.7.1* (56). Reads were then mapped to the zebra finch genome (v3.2.74,6)
372 using *TopHat v2.0.13* (57), which utilizes the aligner *Bowtie v2.2.4* (58). We specified
373 the library type as fr-firststrand in *TopHat2*. Successfully mapped reads were converted
374 from SAM to BAM format with *SAMtools View v1.2* (59,60) and counted in *htseq-count*
375 *v0.6.0* specifying '-s rev' (61). This assigned zebra finch Ensembl gene IDs and we only
376 retained genes that mapped an average of five times across each sample.

377

378 *Differential expression*

379 Gene counts were then normalized for read-depth and analyzed for DE in *DEseq2*
380 *v1.8.1* (28). We analyzed DE across four comparisons: Control vs. Infected, Control vs.

381 2dpi, Control vs. 4dpi, and 2dpi vs. 4dpi. We visualized expression profiles in *R* v3.3.0
382 (62) by PCA with the R package *pcaExplorer* (63), and hierarchical clustering heat maps
383 with the *ggplot2* library (64) following the *DEseq2* manual. *DEseq2* tests for DE with a
384 Wald test and genes were considered differentially expressed if the Benjamini &
385 Hochberg (31) false discovery rate (FDR) correction for multiple testing p value < 0.10 .
386 We chose this significance threshold as *DEseq2* is generally conservative in classifying
387 DE (65). Furthermore, this cutoff has been used in other RNAseq experimental
388 infection studies (66). We plotted genes of interest individually with the *plotCounts*
389 function in *DEseq2* and clustered expression profiles of these genes with the *heatmap* R
390 library to view expression levels across samples and treatments.

391

392 We tested DE genes for under and over representation of gene ontology (GO)
393 categories with the *CORNA* software (<http://www.ark-genomics.org/tools/GOfinch>, [30]).
394 Significant DE genes were tested against all genes in our dataset. Statistical significance
395 was determined using Fisher's exact tests corrected for multiple hypothesis testing ($p <$
396 0.05). To visualize DE results in the context of the RLR pathway, we utilized *Pathview*
397 v1.8.0 (35) to plot the log fold change of each gene detected in our dataset into the Kyoto
398 Encyclopedia of Genes and Genomes (KEGG) pathway (KEGG ID = 04622) (67,68).

399

400 *Time-course gene expression*

401 In addition to the pair-wise comparisons performed in *DEseq2*, we were interested
402 in understanding how clusters of genes are differentially expressed over the time course
403 of infection. Thus, we performed DE analyses in *EBSeqHMM* (29). *EBSeqHMM* utilizes

404 a bayesian approach with a hidden Markov model to identify DE between ordered
405 conditions. Genes are then grouped into expression paths (i.e. “Up-Down”, “Down-
406 Down”), in which DE occurs when expression paths change between at least one adjacent
407 condition. For example, a gene up-regulated at both 2dpi relative to control and 4dpi
408 relative to 2dpi would be classified as “Up-Up”. We included three time points, with
409 control individuals classified as t1, 2dpi as t2 and 4dpi as t3. Genes were considered DE
410 at posterior probability > 0.99 and FDR < 0.01 . We chose a more stringent cutoff in this
411 analysis as *EBseq* can be liberal in classifying differential expression (65) and based on
412 visual inspection of expression profiles. Using genes identified as DE we performed
413 the GO analysis described above.

414

415 *De novo transcriptome analysis*

416 The use of Ensembl gene annotations for read counting restricts analyses to
417 previously annotated genes. To test for potential regulation in any unannotated genes, we
418 created a *de novo* transcriptome from our trimmed, paired-end reads using *Trinity v2.0.6*
419 (36). We used default Trinity parameters with the exception of server specific settings
420 (e.g. `--max_memory 100G`) and strand specificity (`--SS_lib_type RF`). To annotate our
421 transcriptome, we used the *BLASTX*-like aligner *DIAMOND v0.7.11* (37), which utilizes
422 NCBI’s non redundant database. We visualized results in *MEGAN v5.10.6* (38), which
423 places transcripts into functional pathways (e.g. KEGG), facilitating comparisons to our
424 genome based analysis.

425 **References**

426 1. Chancey, C., Grinev, A., Volkova, E. & Rios, M. The Global Ecology and
427 Epidemiology of West Nile Virus. *Biomed Res. Int.* 2015, 20 (2015).

428

- 429 2. Pérez-Ramírez, E., Llorente, F. & Jiménez-Clavero, M. Á. Experimental
430 infections of wild birds with West Nile virus. *Viruses* 6, 752–781 (2014).
431
- 432 3. McLean, R. G. *et al.* West Nile virus transmission and ecology in birds. *Ann N Y*
433 *Acad Sci* 951, 54–57 (2001).
434
- 435 4. LaDeau, S. L., Kilpatrick, a M. & Marra, P. P. West Nile virus emergence and
436 large-scale declines of North American bird populations. *Nature* 447, 710–713 (2007).
437
- 438 5. George, T. L. *et al.* Persistent impacts of West Nile virus on North American bird
439 populations. *Proc. Natl. Acad. Sci. U. S. A.* 1507747112– (2015).
440
- 441 6. Kilpatrick, a M., Daszak, P., Jones, M. J., Marra, P. P. & Kramer, L. D. Host
442 heterogeneity dominates West Nile virus transmission. *Proc. Biol. Sci.* 273, 2327–2333
443 (2006).
444
- 445 7. Komar, N. *et al.* Experimental infection of North American birds with the New
446 York 1999 strain of West Nile virus. *Emerg. Infect. Dis.* 9, 311–322 (2003).
447
- 448 8. Suthar, M. S., Diamond, M. S. & Gale, M. West Nile virus infection and
449 immunity. *Nat. Rev. Microbiol.* 11, 115–28 (2013).
450
- 451 9. Diamond, M. S., Shrestha, B., Mehlhop, E., Sitati, E. & Engle, M. Innate and
452 adaptive immune responses determine protection against disseminated infection by West
453 Nile encephalitis virus. *Viral Immunol.* 16, 259–278 (2003).
454
- 455 10. Diamond, M., Shrestha, B. & Marri, A. B cells and antibody play critical roles in
456 the immediate defense of disseminated infection by West Nile encephalitis virus. *J. Virol.*
457 77, 2578–2586 (2003).
458
- 459 11. Diamond, M. S. & Gale, M. Cell-intrinsic innate immune control of West Nile
460 virus infection. *Trends Immunol.* 33, 522–530 (2012).
461
- 462 12. Errett, J. S., Suthar, M. S., McMillan, A., Diamond, M. S. & Gale, M. The
463 essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile
464 virus infection. *J. Virol.* 87, 11416–25 (2013).
465
- 466 13. Sitati, E. M. & Diamond, M. S. CD4+ T-cell responses are required for clearance
467 of West Nile virus from the central nervous system. *J. Virol.* 80, 12060–12069 (2006).
468
- 469 14. Shrestha, B. & Diamond, M. Role of CD8+ T cells in control of West Nile virus
470 infection. *J. Virol.* 78, 8312–8321 (2004).
471
- 472 15. Lobigs, M., Müllbacher, A. & Regner, M. MHC class I up-regulation by
473 flaviviruses: Immune interaction with unknown advantage to host or pathogen. *Immunol.*
474 *Cell Biol.* 81, 217–223 (2003).

- 475
476 16. Cheng, Y., King, N. J. C. & Kesson, A. M. Major histocompatibility complex
477 class I (MHC-I) induction by West Nile virus: involvement of 2 signaling pathways in
478 MHC-I up-regulation. *J. Infect. Dis.* 189, 658–668 (2004).
479
480 17. Hewitt, E. W. The MHC class I antigen presentation pathway: strategies for viral
481 immune evasion. *Immunology* 110, 163–169 (2003).
482
483 18. Petersen, J. L., Morris, C. R. & Solheim, J. C. Virus evasion of MHC class I
484 molecule presentation. *J. Immunol.* 171, 4473–4478 (2003).
485
486 19. Fair, J. M., Nemeth, N. M., Taylor-McCabe, K. J., Shou, Y. & Marrone, B. L.
487 Clinical and acquired immunologic responses to West Nile virus infection of domestic
488 chickens (*Gallus gallus domesticus*). *Poult. Sci.* 90, 328–336 (2011).
489
490 20. Gamino, V. & Höfle, U. Pathology and tissue tropism of natural West Nile virus
491 infection in birds: A review. *Vet. Res.* 44, (2013).
492
493 21. Tag-El-Din-Hassan, H. T. *et al.* The chicken 2'-5' oligoadenylate synthetase A
494 inhibits the replication of West Nile virus. *Jpn. J. Vet. Res.* 60, 95–103 (2012).
495
496 22. Langevin, S. A., Bunning, M., Davis, B. & Komar, N. Experimental infection of
497 chickens as candidate sentinels for West Nile virus. *Emerg. Infect. Dis.* 7, 726–729
498 (2001).
499
500 23. Balakrishnan, C. N. *et al.* Gene duplication and fragmentation in the zebra finch
501 major histocompatibility complex. *BMC Biol.* 8, 29 (2010).
502
503 24. Bean, A. G. D. *et al.* Studying immunity to zoonotic diseases in the natural host -
504 keeping it real. *Nat. Rev. Immunol.* 13, 851–61 (2013).
505
506 25. Hofmeister, E. K., Lund, M., Shearn-Bochsler, V. & Balakrishnan, C. N.
507 Susceptibility and Antibody Response of the Laboratory Model Zebra Finch
508 (*Taeniopygia guttata*) to West Nile Virus. *PLoS One* 12, e0167876 (2017).
509
510 26. Warren, W. C. *et al.* The genome of a songbird. *Nature* 464, 757–62 (2010).
511
512 27. Hofmeister, E. K., Dusek, R. J., Fassbinder-Orth, C., Owen, B. & Franson, J. C.
513 Susceptibility and antibody response of vesper sparrows (*Pooecetes gramineus*) to West
514 Nile virus: a potential amplification host in sagebrush-grassland habitat. *J. Wildl. Dis.* 52,
515 2015–06–148 (2016).
516
517 28. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
518 dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550 (2014).
519

- 520 29. Leng, N. *et al.* EBSeq-HMM: A Bayesian approach for identifying gene-
521 expression changes in ordered RNA-seq experiments. *Bioinformatics* 31, 2614–2622
522 (2015).
523
- 524 30. Wu, X. & Watson, M. CORNA: Testing gene lists for regulation by microRNAs.
525 *Bioinformatics* 25, 832–833 (2009).
526
- 527 31. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical
528 and powerful approach to multiple testing. *J. R. Stat. Soc.* 57, 289–300 (1995).
529
- 530 32. Barber, M. R., Aldridge Jr., J. R., Webster, R. G. & Magor, K. E. Association of
531 RIG-I with innate immunity of ducks to influenza. *Proc. Natl. Acad. Sci. U. S. A.* 107,
532 5913–5918 (2010).
533
- 534 33. Huang, Y. *et al.* The duck genome and transcriptome provide insight into an avian
535 influenza virus reservoir species. *Nat. Genet.* 45, 776–83 (2013).
536
- 537 34. Wei, L. *et al.* Duck MDA5 functions in innate immunity against H5N1 highly
538 pathogenic avian influenza virus infections. *Vet. Res.* 45, 66 (2014).
539
- 540 35. Luo, W. & Brouwer, C. Pathview: An R/Bioconductor package for pathway-
541 based data integration and visualization. *Bioinformatics* 29, 1830–1831 (2013).
542
- 543 36. Grabherr, M. G. *et al.* Full-length transcriptome assembly from RNA-Seq data
544 without a reference genome. *Nat. Biotechnol.* 29, 644–52 (2011).
545
- 546 37. Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using
547 DIAMOND. *Nat Meth* 12, 59–60 (2015).
548
- 549 38. Huson, D., Mitra, S. & Ruscheweyh, H. Integrative analysis of environmental
550 sequences using MEGAN4. *Genome Res.* 21, 1552–1560 (2011).
551
- 552 39. Takeuchi, O. & Akira, S. Innate immunity to virus infection. *Immunol. Rev.* 227,
553 75–86 (2009).
554
- 555 40. Fassbinder-Orth, C. A., Barak, V. A., Rainwater, E. L. & Altrichter, A. M. Buggy
556 Creek Virus (Togaviridae: Alphavirus) upregulates expression of pattern recognition
557 receptors and interferons in house sparrows (*Passer domesticus*). *Vector-Borne Zoonotic*
558 *Dis.* 14, 439–446 (2014).
559
- 560 41. Jemielity, S. *et al.* TIM-family Proteins Promote Infection of Multiple Enveloped
561 Viruses through Virion-associated Phosphatidylserine. *PLoS Pathog.* 9, (2013).
562
- 563 42. Amara, A. & Mercer, J. Viral apoptotic mimicry. *Nat. Rev. Microbiol.* 13, 461–
564 469 (2015).
565

- 566 43. Qian, F. *et al.* Identification of Genes Critical for Resistance to Infection by West
567 Nile Virus Using RNA-Seq Analysis. *Viruses* 5, (2013).
568
- 569 44. Hussmann, K. L. & Fredericksen, B. L. Differential induction of CCL5 by
570 pathogenic and non-pathogenic strains of West Nile virus in brain endothelial cells and
571 astrocytes. *J. Gen. Virol.* 95, 862–867 (2014).
572
- 573 45. Kumar, M., Belcaid, M. & Nerurkar, V. R. Identification of host genes leading to
574 West Nile virus encephalitis in mice brain using RNA-seq analysis. *Sci. Rep.* 6, 26350
575 (2016).
576
- 577 46. Venter, M. *et al.* Gene expression in mice infected with West Nile virus strains of
578 different neurovirulence. *Virology* 342, 119–140 (2005).
579
- 580 47. Schoggins, J. J. W. *et al.* A diverse array of gene products are effectors of the type
581 I interferon antiviral response. *Nature* 472, 481–485 (2011).
582
- 583 48. Liu, Y., King, N., Kesson, A., Blanden, R. V. & Müllbacher, A. Flavivirus
584 infection up-regulates the expression of class I and class II major histocompatibility
585 antigens on and enhances T cell recognition of astrocytes in vitro. *J. Neuroimmunol.* 21,
586 157–168 (1989).
587
- 588 49. Lobigs, M., Müllbacher, A. & Lee, E. Evidence that a mechanism for efficient
589 flavivirus budding upregulates MHC class I. *Immunol. Cell Biol.* 82, 184–188 (2004).
590
- 591 50. Watzl, C. How to trigger a killer: Modulation of natural killer cell reactivity on
592 many levels. *Adv. Immunol.* 124, (Elsevier Inc., 2014).
593
- 594 51. Kumar, M., Verma, S. & Nerurkar, V. R. Pro-inflammatory cytokines derived
595 from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory
596 markers and neuronal death. *J. Neuroinflammation* 7, 73 (2010).
597
- 598 52. Karim, R. *et al.* Human Papillomavirus (HPV) Upregulates the Cellular
599 Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune Response. *PLoS*
600 *Pathog.* 9, (2013).
601
- 602 53. Brass, A. L. *et al.* The IFITM Proteins Mediate Cellular Resistance to Influenza A
603 H1N1 Virus, West Nile Virus, and Dengue Virus. *Cell* 139, 1243–1254 (2009).
604
- 605 54. Jeurissen, S. H. The role of various compartments in the chicken spleen during an
606 antigen-specific humoral response. *Immunology* 80, 29–33 (1993).
607
- 608 55. Smith, K. G. & Hunt, J. L. On the use of spleen mass as a measure of avian
609 immune system strength. *Oecologia* 138, 28–31 (2004).
610

- 611 56. Martin, M. Cutadapt removes adapter sequences from high-throughput
612 sequencing reads. *EMBnet.journal* 17, 10 (2011).
613
- 614 57. Kim, D. *et al.* TopHat2: accurate alignment of transcriptomes in the presence of
615 insertions, deletions and gene fusions. *Genome Biol.* 14, R36 (2013).
616
- 617 58. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat*
618 *Methods* 9, 357–359 (2012).
619
- 620 59. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics*
621 25, 2078–2079 (2009).
622
- 623 60. Li, H. A statistical framework for SNP calling, mutation discovery, association
624 mapping and population genetical parameter estimation from sequencing data.
625 *Bioinformatics* 27, 2987–2993 (2011).
626
- 627 61. Anders, S., Pyl, P. T. & Huber, W. HTSeq-A Python framework to work with
628 high-throughput sequencing data. *Bioinformatics* 31, 166–169 (2015).
629
- 630 62. R Core Team (2016). R: A language and environment for statistical computing. R
631 Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
632
- 633 63. Marini F (2016). *pcaExplorer: Interactive Visualization of RNA-seq Data Using a*
634 *Principal Components Approach*. R package version
635 1.1.2, <https://github.com/federicomarini/pcaExplorer>.
636
- 637 64. H. Wickham. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New
638 York, 2009.
639
- 640 65. Seyednasrollah, F., Laiho, A. & Elo, L. L. Comparison of software packages for
641 detecting differential expression in RNA-seq studies. *Brief. Bioinform.* 16, 59–70 (2013).
642
- 643 66. Videvall, E., Cornwallis, C. K., Palinauskas, V., Valkiūnas, G. & Hellgren, O.
644 The avian transcriptome response to malaria infection. *Mol. Biol. Evol.* 32, 1255–67
645 (2015).
646
- 647 67. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes.
648 *Nucleic Acids Res.* 28, 27–30 (2000).
649
- 650 68. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a
651 reference resource for gene and protein annotation. *Nucleic Acids Res.* 44, D457–D462
652 (2016).
653
- 654 69. Elbahesh, H., Scherbik, S. V. & Brinton, M. A. West Nile virus infection does not
655 induce PKR activation in rodent cells. *Virology* 421, 51–60 (2011).
656

657

658 **Acknowledgements**

659 The authors wish to thank Melissa Lund for technical assistance. Funding provided by
660 U.S. Geological Survey National Wildlife Health Center and East Carolina University.
661 Any use of trade, firm, or product names is for descriptive purposes only and does not
662 imply endorsement by the U.S. Government

663

664 **Author Contributions**

665 EKH & CNB conceived the study. EKH performed experimental infections and
666 dissection. CNB & DJN extracted and sequenced RNA and performed data analysis. All
667 authors wrote and approved the manuscript.

668

669 **Additional Information**

670 Sequencing data have been deposited in the Sequence Read Archive (SRA) under
671 accession PRJNA352507. The authors declare no competing financial interests

672

673

674

675

700 Table 1. Candidate immune genes differentially expressed in the present study and
 701 comparisons with mammals.
 702

| Ensembl ID | Gene Name | Log ₂ Fold Change | padj | Regulation Pattern Observed | Regulation Pattern in Mammals | Reference |
|----------------------------|----------------------|------------------------------|----------|-----------------------------|-------------------------------|-----------|
| Control vs Infected | | | | | | |
| ENSTGUG00000013615 | NFKBIZ | 0.73 | 0.064 | Up | Up | 45 |
| Control vs 2dpi | | | | | | |
| ENSTGUG00000000297 | IL18 | 1.01 | 0.010 | Up | No change | 51 |
| ENSTGUG00000000678 | TIM1 | 1.49 | 7.99E-05 | Up | Up | 41,42 |
| ENSTGUG00000001485 | IRF6 | -2.09 | 0.037 | Down | Up | 43 |
| ENSTGUG00000003354 | NKRF | -2.35 | 4.85E-05 | Down | Unknown | |
| ENSTGUG00000005295 | C-C motif chemokine | 2.08 | 0.007 | Up | Up | 43,44,45 |
| ENSTGUG00000008638 | UCHL1 | -1.91 | 0.029 | Down | Unknown | |
| ENSTGUG00000008991 | APOD | 1.76 | 0.053 | Up | Up | 46 |
| ENSTGUG00000009454 | IFITM10 | 1.24 | 2.71E-04 | Down | Unknown | |
| ENSTGUG00000009769 | TNFRSF13C | 0.89 | 0.010 | Up | Unknown | |
| ENSTGUG00000015634 | Novel gene (MHC IIB) | 2.23 | 0.001 | Up | Up | 48 |
| ENSTGUG00000016383 | SIGLEC1 | 1.39 | 0.046 | Up | Up | 45 |
| ENSTGUG00000017149 | Novel gene (MHC IIB) | 1.57 | 0.099 | Up | Up | 48 |
| Control vs 4dpi | | | | | | |
| ENSTGUG00000001516 | DDx58 | 1.50 | 1.45E-08 | Up | Up | 45 |
| ENSTGUG00000002144 | IRF4 | 1.39 | 0.022 | Up | Up | 43 |
| ENSTGUG00000002305 | LY86 | -1.07 | 1.70E-05 | Down | Unknown | |
| ENSTGUG00000002516 | DHx58 | 1.67 | 4.05E-06 | Up | Up | 45 |
| ENSTGUG00000004105 | ADAR | 1.13 | 1.70E-05 | Up | Up | 47 |
| ENSTGUG00000006914 | IFIH1 | 0.95 | 0.093 | Up | Up | 45 |
| ENSTGUG00000007454 | TNFRSF13B | 1.61 | 0.010 | Up | Unknown | |
| ENSTGUG00000008354 | IFIT5 | 2.97 | 1.07E-09 | Up | Unknown | |
| ENSTGUG00000008788 | EIF2AK2 | 2.15 | 9.86E-07 | Up | Up | 43,69 |
| ENSTGUG00000009162 | PXK | 1.19 | 0.011 | Up | Unknown | |
| ENSTGUG00000009536 | TRIM25 | 1.24 | 0.001 | Up | Up | 45 |
| ENSTGUG00000009838 | IRF7 | 0.80 | 0.047 | Up | Up | 45 |
| ENSTGUG00000011784 | ZC3HAV1 | 1.31 | 7.09E-08 | Up | Up | 45 |
| ENSTGUG00000017534 | MOV10 | 1.29 | 0.017 | Up | Up | 47 |
| 2dpi vs 4dpi | | | | | | |
| ENSTGUG00000003354 | NKRF | 1.70 | 0.033 | Up | Unknown | |
| ENSTGUG00000005206 | ADA | -1.48 | 0.001 | Down | Unknown | |
| ENSTGUG00000011784 | ZC3HAV1 | 0.82 | 0.058 | Up | Up | 45 |

703

704 Table 2. Select immune related gene ontology (GO) categories among DEseq2
705 significantly differentially expressed genes (adjusted p value < 0.10).
706

| GO ID | Description | Adjusted Fisher |
|------------------------|--|-----------------|
| <i>Control vs 4dpi</i> | | |
| GO:0003727 | single-stranded RNA binding | 0.009 |
| GO:0032481 | positive regulation of type I interferon production | 0.010 |
| GO:0045087 | innate immune response | 0.033 |
| GO:1900245 | positive regulation of MDA-5 signaling pathway | 0.033 |
| GO:1900246 | positive regulation of RIG-I signaling pathway | 0.033 |
| GO:0006926 | virus-infected cell apoptotic process | 0.039 |
| GO:0044319 | wound healing, spreading of cells | 0.039 |
| GO:0032727 | positive regulation of interferon-alpha production | 0.049 |
| GO:0002230 | positive regulation of defense response to virus by host | 0.052 |
| GO:0045088 | regulation of innate immune response | 0.07 |
| <i>2dpi vs 4dpi</i> | | |
| GO:0050862 | positive regulation of T cell receptor signaling pathway | 0.042 |
| GO:0002906 | negative regulation of mature B cell apoptotic process | 0.042 |
| GO:0002686 | negative regulation of leukocyte migration | 0.042 |
| GO:0045580 | regulation of T cell differentiation | 0.042 |
| GO:0032481 | positive regulation of type I interferon production | 0.047 |
| GO:0050870 | positive regulation of T cell activation | 0.057 |

707

676 **Figures:**

677

678 **Figure 1. Immune genes differentially expressed between day 2 post-inoculation and**

679 **control A)** Heatmap of expression levels (log transformed read counts) across all

680 treatments of immune genes differentially expressed at 2dpi relative to control. B-D)

681 Expression values (normalized read counts) for three key immune genes and their

682 regulation pattern classification by *EBSeqHMM*. Asterisks represent statistical

683 significance in *DEseq2* analysis after FDR correction (* $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$).

684

685

686 **Figure 2. Immune genes differentially expressed between day 4 post-inoculation and**

687 **control A)** Heatmap of expression levels (log transformed read counts) across all

688 treatments of immune genes differentially expressed at 4dpi relative to control. B-D)

689 Expression values (normalized read counts) for three key immune genes and their

690 regulation pattern classification by *EBSeqHMM*. Asterisks represent statistical

691 significance in *DEseq2* analysis after FDR correction (* $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$).

692

693

694





695 **Figure 3. Regulation of the zebra finch RLR pathway.** Color represents \log_2 fold





696 change between Control and 4dpi. Asterisks represent statistical significance in *DEseq2*

697 analysis after FDR correction (* $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$).

698

699





RIG-I-LIKE RECEPTOR SIGNALING PATHWAY

